LYEL
Lyell Immunopharma, Inc. Common Stock
stockNASDAQ
we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 10.93 | 2026-10-28 | +40.85% | 1.085 |
| 1M | 9.07 | 2026-10-05 | +69.73% | 0.946 |
| 3M | 13.60 | 2026-08-04 | +13.20% | 0.208 |
| 6M | 20.72 | 2026-05-04 | -25.70% | 1.318 |
| 1Y | 15.95 | 2025-11-04 | -3.48% | 1.434 |
| 2Y | 25.40 | 2024-11-04 | -39.39% | — |
| 5Y | 298.60 | 2021-11-04 | -94.84% | 1.589 |
Lyell Immunopharma, Inc. Common Stock (NASDAQ:LYEL) stock price today is $15.40, and today's volume is 1,014,241. LYEL is up 42.943% today. The 30 day average volume is 151,165. LYEL market cap is $377.26M with 24.51M shares outstanding.